The average settlement for endoscopy complications falls between $250,000 and $463,000, though the actual award depends heavily on the specific injury and medical error. When serious complications occur—such as perforation, hemorrhage, or infection—settlements can climb dramatically. A 2024 Oregon case, for example, resulted in a $25 million verdict after a patient suffered respiratory arrest during a colonoscopy, sustained brain death, and required ongoing intensive care. Endoscopy settlements are not uniform. The 2025 baseline for general medical malpractice claims stands at approximately $463,000 per claim, but endoscopy-specific data shows considerable variation.
Cases involving death or permanent disability regularly exceed $1 million, while less severe injuries may settle in the low six figures. ERCP (endoscopic retrograde cholangiopancreatography) procedures, which carry higher complication risk, average $374,794 per claim—above the broader medical malpractice average. The trajectory of a claim also matters significantly. Data from 40 endoscopy complication cases shows that approximately 35 percent settled, 40 percent were withdrawn, and 25 percent went to trial—with defense verdicts in half of those cases. This means that even serious injuries do not guarantee a large settlement; liability, causation, and evidence all play critical roles.
Table of Contents
- What Do Endoscopy Complication Cases Actually Settle For?
- High-Value Verdicts and Why They Reach Millions
- ERCP vs. Colonoscopy: Which Procedures Generate Higher Settlements?
- What Medical Errors Drive the Largest Payouts?
- How Infection and Device Failures Increase Settlement Value
- Understanding Claim Outcomes and Trial Risk
- Recent FDA Actions and Their Effect on Settlement Leverage
What Do Endoscopy Complication Cases Actually Settle For?
Endoscopy complication settlements cluster around several distinct price tiers. The median settlement sits near $300,000 to $400,000 for cases involving moderate to severe injury. A 2024 Massachusetts case paid $1.5 million after a patient suffered a splenic injury and internal bleeding during colonoscopy, while a 2014 Massachusetts case settled for $1 million in a general colonoscopy malpractice claim. The difference often hinges on permanence of injury, quality of evidence of negligence, and whether the patient survived. Lower-tier settlements—$250,000 to $600,000—typically involve injuries that required hospitalization and treatment but did not result in death or permanent cognitive impairment.
A Connecticut case paid $575,000 when clinicians failed to diagnose an esophageal perforation during balloon dilation, leaving the injury undetected long enough to cause serious damage. Mid-tier settlements, from $600,000 to $1.5 million, reflect injuries with significant morbidity: sepsis, organ damage, or prolonged disability. An Illinois case from 2017 reached $1.1 million after a 90-year-old suffered colon perforation during colonoscopy, triggering septic shock. The gap between “typical” settlements and catastrophic verdicts is substantial. Most claims fall under $500,000, but cases involving death or permanent brain injury often exceed this threshold significantly. This variation makes individual settlement amounts unreliable as prediction tools; instead, understanding the injury category and strength of liability evidence provides better guidance.
High-Value Verdicts and Why They Reach Millions
Settlements exceed $2 million when the case involves death, permanent cognitive disability, or a clear pattern of negligence by hospital or physician staff. The $25 million Oregon verdict came after a patient arrested during colonoscopy; evidence showed inadequate resuscitation and failure to intervene appropriately. The $15.1 million Tennessee verdict resulted from death after ERCP-induced hemorrhagic shock—a known complication made worse by delayed recognition and inadequate blood product replacement. A $4.5 million Iowa case centered on a woman who died from internal bleeding post-ERCP, with liability anchored in deviation from standard care during and after the procedure. Device failures and hospital-acquired infections also drive settlements upward. A $6.6 million Seattle settlement involved an Olympus duodenoscope superbug outbreak; the family of a deceased patient received $1 million from that settlement pool.
When manufacturers knew or should have known about device contamination but failed to warn clinicians, settlements reflect both the injury and the corporate negligence. A Connecticut case paying $2.65 million involved a 63-year-old who suffered a brain bleed after endoscopy with documented Heparin overdose—a medication error compounding the procedural risk. The limitation of high-value verdicts is that they represent outliers, not baselines. Juries are more likely to award millions when negligence is egregious, the patient is sympathetic, and damages are permanent. A death in a young patient with surviving children will command higher sympathy than the same complication in an elderly patient with terminal illness. Moreover, many high-value cases are tried verdicts, not settlements; insurance companies often settle lower to avoid jury risk, and families sometimes accept smaller settlements to avoid the delay and publicity of trial.
ERCP vs. Colonoscopy: Which Procedures Generate Higher Settlements?
ERCP carries higher settlement value than colonoscopy, reflecting its greater complication risk. The mean payout for ERCP-related claims is $374,794 per closed claim, while colonoscopy cases across 788 closed claims generated $54.1 million in total indemnities—averaging approximately $68,600 per claim. However, this lower average masks high-value outliers in the colonoscopy cohort. When a colonoscopy goes catastrophically wrong, the settlement can rival or exceed ERCP outcomes; the $25 million Oregon verdict was a colonoscopy complication, not ERCP. The procedural risk hierarchy reflects complication frequency and severity. Colonoscopy carries a 1.7x risk multiplier, ERCP 1.6x, esophagogastroduodenoscopy (EGD) 1.2x, and sigmoidoscopy baseline at 1.0x.
This means that colonoscopy claims are statistically more frequent, but ERCP claims tend to involve more severe harm when complications occur. ERCP complications often include pancreatic injury, hemorrhage, and perforation; these injuries frequently require surgery or intensive care, inflating settlement value. Colonoscopy complications include perforation and hemorrhage but are more often managed conservatively with antibiotics and observation if caught early. The practical limitation is that procedure type alone does not determine settlement size. A straightforward ERCP complication caught early and treated appropriately might settle for $200,000, while a delayed perforation during colonoscopy—requiring emergency surgery and leaving the patient with an ostomy—might settle for $800,000 or more. Liability evidence, medical causation, and injury permanence outweigh the statistical risk multipliers in individual cases.
What Medical Errors Drive the Largest Payouts?
The largest settlements stem from errors in resuscitation, medication dosing, and post-procedural monitoring. The $25 million Oregon case pivoted on inadequate resuscitation after respiratory arrest. The $4.5 million Iowa case involved failure to monitor and intervene during post-ERCP hemorrhage. The $2.65 million Connecticut case centered on Heparin overdose—a medication safety failure during endoscopy. These verdicts align with the principle that juries and insurers treat clinician error more harshly than inherent procedure risk. Failure to recognize or diagnose complications ranks second in settlement drivers.
The $575,000 Connecticut settlement for missed esophageal perforation reflects the principle that early diagnosis and intervention limit damage. A patient whose perforation is discovered within hours and treated surgically has far better outcomes than one whose perforation goes unrecognized for 24 hours, allowing sepsis to develop. Lawyers in these cases emphasize the “golden window” for diagnosis and treatment, arguing that standard care required vigilance for warning signs (fever, abdominal pain, shoulder pain from pneumoperitoneum) and rapid imaging. The warning is that even proper recognition of a complication does not guarantee a low settlement if the complication itself is rare and the patient’s risk factors were not clearly communicated beforehand. Informed consent becomes a secondary issue in cases where consent was obtained but complication risk was minimized. A patient who was told “perforation occurs in 1 in 1,000 colonoscopies” may perceive different risk than one told “perforation occurs in 1 in 500 to 1 in 3,000 depending on polyp size and technique.” Vague risk disclosure, even with a signature, can worsen settlement exposure.
How Infection and Device Failures Increase Settlement Value
Hospital-acquired infections from contaminated endoscopes have become a major settlement driver. The $6.6 million Seattle settlement from Olympus duodenoscope contamination demonstrates that when device manufacturers fail to adequately address known infection risks, settlements reflect both the injury and the corporate negligence component. Similarly, a $43 million Pentax mass settlement addressed misbranded endoscopes and unreported infections, affecting dozens of patients across multiple facilities. These settlements exceed individual injury value because they include punitive damages and recognize systemic failures rather than isolated provider negligence. Recent FDA Class I recalls heighten settlement leverage. In February 2025, the FDA issued a Class I recall for the Olympus MAJ-891 accessory, citing 120 injuries and 1 death. In October 2025, Olympus TJF duodenoscope bacterial infection issues led to additional safety warnings.
Between 2024 and October 2025, Olympus device-related infections caused 2 deaths and 5 serious injuries reported to the FDA. Patients who develop healthcare-associated infections traceable to defective equipment now have stronger claims against both the healthcare facility and the device manufacturer. The limitation in infection-based claims is causation. A patient who develops an infection after endoscopy must prove that the specific organism came from the endoscope, not from their own flora or another environmental source. Defense counsel will argue normal colonoscopy risk and comorbid factors. However, when patient populations at multiple facilities develop the same organism shortly after use of a specific device model, epidemiologic evidence shifts the burden. Hospital records showing inadequate endoscope reprocessing, FDA safety alerts, and device manufacturer internal communications often become the most valuable discovery items in these cases.
Understanding Claim Outcomes and Trial Risk
Fifty percent of endoscopy cases that proceed to trial result in defense verdicts, meaning the jury finds no liability or insufficient damages despite a serious injury. This fact alone explains why many plaintiffs accept settlements well below their case’s theoretical value—trial risk is real. Of 40 endoscopy complication cases studied, 14 settled (35 percent), 16 were withdrawn (40 percent), and 10 went to trial (25 percent). Withdrawal rates are high because many cases lack clear liability evidence; a complication can occur despite appropriate care in rare instances.
Settlement negotiations often hinge on this trial risk calculation. If an expert concludes the complication was unavoidable despite reasonable care, the case value drops sharply. If the same expert concludes the complication resulted from deviation from standard care (inadequate informed consent, failure to recognize warning signs, improper technique), the settlement expectation rises. Insurance companies price settlements based on jury pool composition, judge reputation, and region as much as on injury severity. A case in a conservative jurisdiction may settle for $300,000 despite $1 million jury demand, because the defense estimates a 40 percent trial loss probability and local juries historically award below national averages.
Recent FDA Actions and Their Effect on Settlement Leverage
The February 2025 FDA Class I recall of the Olympus MAJ-891 accessory created immediate settlement pressure for cases involving that device. Patients with documented use of the recalled accessory before the warning date now have stronger causation arguments; the FDA’s determination of a public health hazard shifts the burden toward device manufacturer liability. Any settlement involving this accessory issued after February 2025 reflects the FDA determination and carries higher value than pre-recall settlements would have.
The October 2025 Olympus TJF duodenoscope bacterial infection warnings, combined with the reported 2 deaths and 5 serious injuries between 2024 and October 2025, have prompted hospitals and medical malpractice insurers to proactively reach settlements in pending cases. Healthcare facilities facing both patient liability and potential corporate negligence claims (for inadequate reprocessing protocols) are more likely to settle aggressively. The Pentax $43 million mass settlement, arising from misbranded devices and unreported infections, establishes precedent that device failures can generate seven-figure individual settlements when patients can link their infections to specific equipment recalls or FDA safety communications.
- —